95 related articles for article (PubMed ID: 19966851)
1. Genetic polymorphisms associated with outcome in multiple myeloma patients receiving high-dose melphalan.
Dumontet C; Landi S; Reiman T; Perry T; Plesa A; Bellini I; Barale R; Pilarski LM; Troncy J; Tavtigian S; Gemignani F
Bone Marrow Transplant; 2010 Aug; 45(8):1316-24. PubMed ID: 19966851
[TBL] [Abstract][Full Text] [Related]
2. Comparison of high-dose melphalan with a more intensive regimen of thiotepa, busulfan, and cyclophosphamide for patients with multiple myeloma.
Anagnostopoulos A; Aleman A; Ayers G; Donato M; Champlin R; Weber D; Alexanian R; Giralt S
Cancer; 2004 Jun; 100(12):2607-12. PubMed ID: 15197803
[TBL] [Abstract][Full Text] [Related]
3. Glomerular filtration rate prior to high-dose melphalan 200 mg/m(2) as a surrogate marker of outcome in patients with myeloma.
Sirohi B; Powles R; Kulkarni S; Rudin C; Saso R; Rigg A; Horton C; Singhal S; Mehta J; Treleaven J
Br J Cancer; 2001 Aug; 85(3):325-32. PubMed ID: 11487259
[TBL] [Abstract][Full Text] [Related]
4. Impact on response and survival of DNA repair single nucleotide polymorphisms in relapsed or refractory multiple myeloma patients treated with thalidomide.
Cibeira MT; de Larrea CF; Navarro A; Díaz T; Fuster D; Tovar N; Rosiñol L; Monzó M; Bladé J
Leuk Res; 2011 Sep; 35(9):1178-83. PubMed ID: 21435719
[TBL] [Abstract][Full Text] [Related]
5. Short and long-term outcome of treatment with high-dose melphalan and stem cell transplantation for multiple myeloma-associated AL amyloidosis.
Girnius S; Seldin DC; Skinner M; Finn KT; Quillen K; Doros G; Sanchorawala V
Ann Hematol; 2010 Jun; 89(6):579-84. PubMed ID: 20012043
[TBL] [Abstract][Full Text] [Related]
6. Long-term outcomes of previously untreated myeloma patients: responses to induction chemotherapy and high-dose melphalan incorporated within a risk stratification model can help to direct the use of novel treatments.
Alvares CL; Davies FE; Horton C; Patel G; Powles R; Sirohi B; Zuha R; Gatt A; Saso R; Treleaven JG; Dearden CE; Potter MN; Ethell ME; Morgan GJ
Br J Haematol; 2005 Jun; 129(5):607-14. PubMed ID: 15916682
[TBL] [Abstract][Full Text] [Related]
7. Extent of damage and repair in the p53 tumor-suppressor gene after treatment of myeloma patients with high-dose melphalan and autologous blood stem-cell transplantation is individualized and may predict clinical outcome.
Dimopoulos MA; Souliotis VL; Anagnostopoulos A; Papadimitriou C; Sfikakis PP
J Clin Oncol; 2005 Jul; 23(19):4381-9. PubMed ID: 15883412
[TBL] [Abstract][Full Text] [Related]
8. Genetic variants in DNA repair pathways are not associated with disease progression among multiple myeloma patients.
Thyagarajan B; Arora M; Guan W; Barcelo H; Jackson S; Kumar S; Gertz M
Leuk Res; 2013 Nov; 37(11):1527-31. PubMed ID: 24129343
[TBL] [Abstract][Full Text] [Related]
9. Combined submyeloablative and myeloablative dose intense melphalan results in satisfactory responses with acceptable toxicity in patients with multiple myeloma.
Novitzky N; Thomson J; Thomas V; du Toit C; Mohamed Z; McDonald A
Biol Blood Marrow Transplant; 2010 Oct; 16(10):1402-10. PubMed ID: 20385248
[TBL] [Abstract][Full Text] [Related]
10. [Comparison of regimen-related toxicity between high-dose melphalan and ICE as a preparatory regimen for autologous stem cell transplantation].
Imataki O; Aoyama T; Tamai Y; Kawakami K
Gan To Kagaku Ryoho; 2007 Oct; 34(10):1633-6. PubMed ID: 17940379
[TBL] [Abstract][Full Text] [Related]
11. Genetic polymorphisms in the amino acid transporters LAT1 and LAT2 in relation to the pharmacokinetics and side effects of melphalan.
Kühne A; Kaiser R; Schirmer M; Heider U; Muhlke S; Niere W; Overbeck T; Hohloch K; Trümper L; Sezer O; Brockmöller J
Pharmacogenet Genomics; 2007 Jul; 17(7):505-17. PubMed ID: 17558306
[TBL] [Abstract][Full Text] [Related]
12. Intermediate-dose (25mg/m2) IV melphalan for multiple myeloma with renal failure.
Vigneau C; Ardiet C; Bret M; Laville M; Fiere D; Tranchand B; Fouque D
J Nephrol; 2002; 15(6):684-9. PubMed ID: 12495285
[TBL] [Abstract][Full Text] [Related]
13. Single nucleotide polymorphisms in DNA repair genes XRCC1 and APEX1 in progression and survival of primary cutaneous melanoma patients.
Figl A; Scherer D; Nagore E; Bermejo JL; Dickes E; Thirumaran RK; Gast A; Hemminki K; Kumar R; Schadendorf D
Mutat Res; 2009 Feb; 661(1-2):78-84. PubMed ID: 19073198
[TBL] [Abstract][Full Text] [Related]
14. Response to chemotherapy and tandem autologous transplantation of multiple myeloma patients and GSTP1 and TYMS polymorphisms.
Maggini V; Buda G; Galimberti S; Conidi E; Giuliani N; Morabito F; Genestreti G; Iacopino P; Rizzoli V; Barale R; Petrini M; Rossi AM
Leuk Res; 2008 Jan; 32(1):49-53. PubMed ID: 17512053
[TBL] [Abstract][Full Text] [Related]
15. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.
San Miguel JF; Schlag R; Khuageva NK; Dimopoulos MA; Shpilberg O; Kropff M; Spicka I; Petrucci MT; Palumbo A; Samoilova OS; Dmoszynska A; Abdulkadyrov KM; Schots R; Jiang B; Mateos MV; Anderson KC; Esseltine DL; Liu K; Cakana A; van de Velde H; Richardson PG;
N Engl J Med; 2008 Aug; 359(9):906-17. PubMed ID: 18753647
[TBL] [Abstract][Full Text] [Related]
16. Melphalan-induced DNA damage in vitro as a predictor for clinical outcome in multiple myeloma.
Dimopoulos MA; Souliotis VL; Anagnostopoulos A; Bamia C; Pouli A; Baltadakis I; Terpos E; Kyrtopoulos SA; Sfikakis PP
Haematologica; 2007 Nov; 92(11):1505-12. PubMed ID: 18024399
[TBL] [Abstract][Full Text] [Related]
17. Outcome assessment of a population-based group of 195 unselected myeloma patients under 70 years of age offered intensive treatment.
Powles R; Raje N; Milan S; Millar B; Shepherd V; Mehta J; Singhal S; Kulkarni S; Viner C; Gore M; Cunningham D; Treleaven J
Bone Marrow Transplant; 1997 Sep; 20(6):435-43. PubMed ID: 9313875
[TBL] [Abstract][Full Text] [Related]
18. Oral mucositis in myeloma patients undergoing melphalan-based autologous stem cell transplantation: incidence, risk factors and a severity predictive model.
Grazziutti ML; Dong L; Miceli MH; Krishna SG; Kiwan E; Syed N; Fassas A; van Rhee F; Klaus H; Barlogie B; Anaissie EJ
Bone Marrow Transplant; 2006 Oct; 38(7):501-6. PubMed ID: 16980998
[TBL] [Abstract][Full Text] [Related]
19. Single-nucleotide polymorphisms in DNA double-strand break repair genes: association with head and neck cancer and interaction with tobacco use and alcohol consumption.
Werbrouck J; De Ruyck K; Duprez F; Van Eijkeren M; Rietzschel E; Bekaert S; Vral A; De Neve W; Thierens H
Mutat Res; 2008 Oct; 656(1-2):74-81. PubMed ID: 18768166
[TBL] [Abstract][Full Text] [Related]
20. Melphalan-prednisone versus alternating combination VAD/MP or VND/MP as primary therapy for multiple myeloma: final analysis of a randomized clinical study.
Cavo M; Benni M; Ronconi S; Fiacchini M; Gozzetti A; Zamagni E; Cellini C; Tosi P; Baccarani M; Tura S;
Haematologica; 2002 Sep; 87(9):934-42. PubMed ID: 12217805
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
